Search research articles
Contact Us
Filters
Showing results (141-150 of 163) with videos related to
Page
of 17
Sort By:
Therapeutic Advances in Neurological Disorders
|
March 28, 2020
Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
Munenori Oyama, Kensuke Okada, Masayuki Masuda, et al.
The Lancet. Neurology
|
October 26, 2017
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F Howard, Kimiaki Utsugisawa, Michael Benatar, et al.
Expert Review of Clinical Immunology
|
April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases
Kelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
Frontiers in Neurology
|
February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
James F Howard, Vera Bril, Tuan Vu, et al.
Neurology. Clinical Practice
|
March 28, 2024
Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan
Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, et al.
BMJ Open
|
January 31, 2023
Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
Sarah Dewilde, Glenn Philips, Sandra Paci, et al.
Rinsho Shinkeigaku = Clinical Neurology
|
June 23, 2017
Questionnaire survey on the process of specialty training in neurology in Japan
Masahiro Sonoo, Kazutoshi Nishiyama, Tetsuo Ando, et al.
The Lancet. Neurology
|
November 19, 2020
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
Srikanth Muppidi, Jeffrey T Guptill, Saiju Jacob, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
November 19, 2004
Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease
Yasumasa Ohyagi, Hideaki Asahara, De-Hua Chui, et al.
Annals of Clinical and Translational Neurology
|
April 4, 2024
Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 163) with videos related to
Sort By:
Page
of 17
Therapeutic Advances in Neurological Disorders
|
March 28, 2020
Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis
Munenori Oyama, Kensuke Okada, Masayuki Masuda, et al.
The Lancet. Neurology
|
October 26, 2017
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F Howard, Kimiaki Utsugisawa, Michael Benatar, et al.
Expert Review of Clinical Immunology
|
April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases
Kelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
Frontiers in Neurology
|
February 6, 2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
James F Howard, Vera Bril, Tuan Vu, et al.
Neurology. Clinical Practice
|
March 28, 2024
Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan
Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, et al.
BMJ Open
|
January 31, 2023
Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG
Sarah Dewilde, Glenn Philips, Sandra Paci, et al.
Rinsho Shinkeigaku = Clinical Neurology
|
June 23, 2017
Questionnaire survey on the process of specialty training in neurology in Japan
Masahiro Sonoo, Kazutoshi Nishiyama, Tetsuo Ando, et al.
The Lancet. Neurology
|
November 19, 2020
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
Srikanth Muppidi, Jeffrey T Guptill, Saiju Jacob, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
November 19, 2004
Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease
Yasumasa Ohyagi, Hideaki Asahara, De-Hua Chui, et al.
Annals of Clinical and Translational Neurology
|
April 4, 2024
Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, et al.
Page
of 17